Organon & Co. (NYSE:OGN – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, August 6th. Analysts expect the company to announce earnings of $1.15 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Organon & Co. (NYSE:OGN – Get Free Report) last posted its earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.31. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The business had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.57 billion. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Organon & Co. Price Performance
OGN stock opened at $20.91 on Monday. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.08. The firm has a market cap of $5.38 billion, a P/E ratio of 5.11, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85. The stock has a 50-day simple moving average of $20.89 and a 200-day simple moving average of $19.23.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Organon & Co.
About Organon & Co.
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Further Reading
- Five stocks we like better than Organon & Co.
- What is a Special Dividend?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What Is WallStreetBets and What Stocks Are They Targeting?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Using the MarketBeat Stock Split Calculator
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.